Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULMGet Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Pulmatrix in a research report on Tuesday, August 15th.

Get Our Latest Stock Analysis on PULM

Pulmatrix Stock Down 3.2 %

PULM stock opened at $1.81 on Tuesday. The firm’s 50-day simple moving average is $2.13 and its 200 day simple moving average is $2.52. The stock has a market cap of $6.61 million, a PE ratio of -0.37 and a beta of 0.77. Pulmatrix has a fifty-two week low of $1.76 and a fifty-two week high of $4.49.

Pulmatrix (NASDAQ:PULMGet Free Report) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.19. The firm had revenue of $1.84 million for the quarter, compared to analysts’ expectations of $1.51 million. Pulmatrix had a negative net margin of 253.24% and a negative return on equity of 60.14%. Equities analysts forecast that Pulmatrix will post -4.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Pulmatrix

Several hedge funds and other institutional investors have recently made changes to their positions in PULM. Renaissance Technologies LLC increased its stake in shares of Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,300 shares during the last quarter. Citadel Advisors LLC acquired a new position in Pulmatrix during the second quarter worth approximately $141,000. Mariner LLC acquired a new position in Pulmatrix during the fourth quarter worth approximately $97,000. Finally, Susquehanna International Group LLP bought a new stake in Pulmatrix in the first quarter valued at approximately $73,000. 11.62% of the stock is owned by institutional investors.

Pulmatrix Company Profile

(Get Free Report)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Featured Stories

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.